Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
547 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypertension - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2017, provides an overview of the Hypertension (Cardiovascular) pipeline landscape. Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 35, 35, 31, 89, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 11 molecules, respectively. Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Hypertension - Overview 8 Hypertension - Therapeutics Development 9 Hypertension - Therapeutics Assessment 36 Hypertension - Companies Involved in Therapeutics Development 54 Hypertension - Drug Profiles 111 Hypertension - Dormant Projects 497 Hypertension - Discontinued Products 511 Hypertension - Product Development Milestones 513 Appendix 522
List of Tables
Number of Products under Development for Hypertension, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Hypertension - Pipeline by A1M Pharma AB, H1 2017 Hypertension - Pipeline by Actelion Ltd, H1 2017 Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by AnGes MG Inc, H1 2017 Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017 Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017 Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Bayer AG, H1 2017 Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017 Hypertension - Pipeline by Biolab Farmaceutica Ltda, H1 2017 Hypertension - Pipeline by BioRestorative Therapies Inc, H1 2017 Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017 Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2017 Hypertension - Pipeline by Camurus AB, H1 2017 Hypertension - Pipeline by Capricor Therapeutics Inc, H1 2017 Hypertension - Pipeline by Celsion Corp, H1 2017 Hypertension - Pipeline by Celtaxsys Inc, H1 2017 Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017 Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 Hypertension - Pipeline by CJ HealthCare Corp, H1 2017 Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Corion Biotech Srl, H1 2017 Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Cytokinetics Inc, H1 2017 Hypertension - Pipeline by Daewoong Co Ltd, H1 2017 Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Hypertension - Pipeline by DiaMedica Therapeutics Inc, H1 2017 Hypertension - Pipeline by Eli Lilly and Company, H1 2017 Hypertension - Pipeline by Esperion Therapeutics Inc, H1 2017 Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Hypertension - Pipeline by Ferring International Center SA, H1 2017 Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017 Hypertension - Pipeline by Gemphire Therapeutics Inc, H1 2017 Hypertension - Pipeline by Gilead Sciences Inc, H1 2017 Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2017 Hypertension - Pipeline by H. Lundbeck A/S, H1 2017 Hypertension - Pipeline by HanAll Biopharma Co Ltd, H1 2017 Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 Hypertension - Pipeline by HitGen LTD, H1 2017 Hypertension - Pipeline by Innopharmax Inc, H1 2017 Hypertension - Pipeline by Insmed Inc, H1 2017 Hypertension - Pipeline by Insys Therapeutics Inc, H1 2017 Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 Hypertension - Pipeline by Johnson & Johnson, H1 2017 Hypertension - Pipeline by JW Pharmaceutical Corp, H1 2017 Hypertension - Pipeline by Kowa Company Ltd, H1 2017 Hypertension - Pipeline by Leading BioSciences Inc, H1 2017 Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017 Hypertension - Pipeline by Les Laboratoires Servier�SAS, H1 2017 Hypertension - Pipeline by LinXis BV, H1 2017 Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017 Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017 Hypertension - Pipeline by MannKind Corp, H1 2017 Hypertension - Pipeline by Marina Biotech Inc, H1 2017 Hypertension - Pipeline by Merck & Co Inc, H1 2017 Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017 Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017 Hypertension - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2017 Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017 Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017 Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017 Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017 Hypertension - Pipeline by Novartis AG, H1 2017 Hypertension - Pipeline by Noxamet Ltd, H1 2017 Hypertension - Pipeline by Omeros Corp, H1 2017 Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017 Hypertension - Pipeline by Pfizer Inc, H1 2017 Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017 Hypertension - Pipeline by Polyphor Ltd, H1 2017 Hypertension - Pipeline by Pulmokine Inc, H1 2017 Hypertension - Pipeline by Quantum Genomics SA, H1 2017 Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by RedHill Biopharma Ltd, H1 2017 Hypertension - Pipeline by Relypsa Inc, H1 2017 Hypertension - Pipeline by Renova Therapeutics Inc, H1 2017 Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017 Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017 Hypertension - Pipeline by rEVO Biologics Inc, H1 2017 Hypertension - Pipeline by Rottapharm Biotech Srl, H1 2017 Hypertension - Pipeline by Sanofi, H1 2017 Hypertension - Pipeline by Savara Inc, H1 2017 Hypertension - Pipeline by Serodus ASA, H1 2017 Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017 Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017 Hypertension - Pipeline by Simcere Pharmaceutical Group, H1 2017 Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017 Hypertension - Pipeline by Suda Ltd, H1 2017 Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Hypertension - Pipeline by The Medicines Company, H1 2017 Hypertension - Pipeline by Theravance Biopharma Inc, H1 2017 Hypertension - Pipeline by Toray Industries Inc, H1 2017 Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017 Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H1 2017 Hypertension - Pipeline by United Therapeutics Corp, H1 2017 Hypertension - Pipeline by Vascular BioSciences, H1 2017 Hypertension - Pipeline by Vectura Group Plc, H1 2017 Hypertension - Pipeline by VG Life Sciences Inc, H1 2017 Hypertension - Pipeline by Vicore Pharma AB, H1 2017 Hypertension - Pipeline by Vivus Inc, H1 2017 Hypertension - Pipeline by XORTX Pharma Corp, H1 2017 Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H1 2017 Hypertension - Pipeline by Yuhan Corp, H1 2017 Hypertension - Dormant Projects, H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..2), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..3), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..4), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..5), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..6), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..7), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..8), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..9), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..10), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..11), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..12), H1 2017 Hypertension - Dormant Projects, H1 2017 (Contd..13), H1 2017 Hypertension - Discontinued Products, H1 2017 Hypertension - Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
